SAREPTA THERAPEUTICS INC

NASDAQ: SRPT (Sarepta Therapeutics, Inc.)

最近更新时间: 6天之前, 4:21AM

23.83

0.68 (2.94%)

前收盘价格 23.15
收盘价格 23.67
成交量 1,999,440
平均成交量 (3个月) 4,229,547
市值 2,497,078,528
预期市盈率 (P/E Forward) 16.98
价格/销量 (P/S) 0.970
股市价格/股市净资产 (P/B) 1.67
52周波幅
10.42 (-56%) — 127.91 (436%)
利润日期 3 Nov 2025
营业毛利率 -11.12%
营业利益率 (TTM) -40.33%
稀释每股收益 (EPS TTM) -2.64
季度收入增长率 (YOY) 80.20%
季度盈利增长率 (YOY) 248.40%
总债务/股东权益 (D/E MRQ) 118.73%
流动比率 (MRQ) 4.02
营业现金流 (OCF TTM) -547.15 M
杠杆自由现金流 (LFCF TTM) -741.26 M
资产报酬率 (ROA TTM) -2.19%
股东权益报酬率 (ROE TTM) -23.61%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 Sarepta Therapeutics, Inc. 看跌 看跌

AIStockmoo 评分

-2.5
分析师共识 -3.5
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 -2.5
技术振荡指标 -2.0
平均 -2.50

相关股票

股票 市值 DY P/E(TTM) P/B
SRPT 2 B - - 1.67
RVMD 22 B - - 14.36
IONS 13 B - - 21.05
NUVL 8 B - - 9.71
CRNX 6 B - - 5.09
IMVT 5 B - - 10.09

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 4.42%
机构持股比例 96.33%

所有权

姓名 日期 持有股份
Erste Asset Management Gmbh 30 Sep 2025 2,685,945
52周波幅
10.42 (-56%) — 127.91 (436%)
目标价格波幅
5.00 (-79%) — 45.00 (88%)
45.00 (Wells Fargo, 88.84%) 购买
19.50 (-18.17%)
5.00 (HC Wainwright & Co., -79.02%) 卖出
平均值 22.25 (-6.63%)
总计 4 购买, 3 保留, 1 卖出
平均价格@调整类型 19.68
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 14 Jan 2026 5.00 (-79.02%) 卖出 21.15
Wedbush 09 Dec 2025 32.00 (34.28%) 购买 22.17
Barclays 05 Nov 2025 20.00 (-16.07%) 保留 18.67
Guggenheim 05 Nov 2025 19.00 (-20.27%) 购买 18.67
Mizuho 05 Nov 2025 26.00 (9.11%) 购买 18.67
Wells Fargo 05 Nov 2025 45.00 (88.84%) 购买 18.67
Baird 04 Nov 2025 15.00 (-37.05%) 保留 16.20
Piper Sandler 30 Oct 2025 16.00 (-32.86%) 保留 23.25

该时间范围内无数据。

日期 类型 细节
12 Jan 2026 公告 Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
07 Jan 2026 公告 Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
05 Jan 2026 公告 Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
31 Dec 2025 公告 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Dec 2025 公告 Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
25 Nov 2025 公告 Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
24 Nov 2025 公告 Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
24 Nov 2025 公告 Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
14 Nov 2025 公告 Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
03 Nov 2025 公告 Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
27 Oct 2025 公告 Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
21 Oct 2025 公告 Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票